PVCT President Dominic Rodrigues Buys 45,860 Shares
Provectus Biopharmaceuticals' president, Dominic Rodrigues, bought shares amid a wave of insider transactions.
Reviewed by automated data checks against the source filing. How we make and check alerts
Dominic Rodrigues, PRESIDENT at Provectus Biopharmaceuticals, Inc. ($PVCT), bought 45,860 shares on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PVCT is up 0.0% after 1 week, down 14.3% after 1 month and down 28.6% to date (from the $0.07 close on Jun 30, 2026).
PVCT
Provectus Biopharmaceuticals, Inc.
Key Points
- On June 30, 2026, Dominic Rodrigues, president of Provectus Biopharmaceuticals, acquired 45,860 shares of the company, reflecting his confidence in its future.
- Provectus Biopharmaceuticals, a clinical-stage biotechnology firm focused on immunotherapy medicines, has a market cap of approximately $23.5 million.
- Insider buying is notable as other executives, including Webster Bailey and Lacey John III, also purchased shares on the same day.
Get $PVCT trade alerts by text
We text you when insiders, Congress or big funds trade $PVCT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Provectus Biopharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Provectus Biopharmaceuticals, Inc.
On June 30, 2026, Dominic Rodrigues, the president of Provectus Biopharmaceuticals, Inc. (PVCT), bought 45,860 shares of the company, marking a significant insider purchase. This transaction occurred on the OTC Markets OTCQB exchange, where the stock was trading at about $0.07 at the time of the purchase.
Notable Activity from Other Insiders
Rodrigues isn't alone in his buying spree. On the same day, Webster Bailey and Lacey John III each acquired 48,917 shares of Provectus Biopharmaceuticals. These purchases collectively indicate a strong interest from the company's leadership, which may reflect their confidence in the company's direction and ongoing projects.
Stock Performance and Market Context
As of the publication date, Provectus Biopharmaceuticals shares were trading around $0.07, which is above its 52-week low of $0.04 but below its high of $0.09. This context suggests that the stock is in a relatively stable range, appealing to insiders who may see potential for growth in the company's biotechnology developments.
What Provectus Biopharmaceuticals, Inc. Does
Provectus Biopharmaceuticals, Inc. focuses on developing immunotherapy treatments for various diseases, including melanoma and liver cancers. The company's lead product, PV-10, is in clinical trials, and its ongoing research aims to expand treatment options for serious health conditions. The recent insider buying could signal a belief in the company's upcoming advancements and market potential.
What’s Next for Provectus?
Looking ahead, investors will be watching for further updates on Provectus Biopharmaceuticals’ clinical trials and the next earnings report scheduled for August 11, 2025. The recent insider transactions reflect past positions and may not represent current holdings, but they do highlight ongoing interest from the company's leadership in its future prospects.
Related Filing Alerts
Source: Dominic Rodrigues's Form 4 filing on $PVCT (Jun 30, 2026). Find the original filing: PVCT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts